Primary lymphoma of the central nervous system: Epidemiology, pathology and current approaches to diagnosis, prognosis and treatment

James Rubenstein, Andres J M Ferreri, Stefania Pittaluga

Research output: Contribution to journalArticle

Abstract

An overview of the current approaches to the management of patients with primary central nervous system lymphoma (PCNSL) is provided. Although accumulating evidence demonstrates that PCNSL is a curable type of brain tumor, in many cases establishing the diagnosis and overcoming chemotherapeutic resistance remain significant obstacles. The issue of treatment-related neurotoxicity is also a central consideration in treatment planning. The introduction of highly active antiretroviral therapy has had a major impact on this disease in that the incidence of AIDS-related central nervous system lymphoma, once highly prevalent in the 1980s and 1990s, has now virtually disappeared. However, the problem of diagnostic delays secondary to steroid effects, radiation-induced neurotoxicity and methotrexate resistance represent unique and important problems in this disease. The use of anti-CD20 antibody in this disease represents the first application of biologically based targeted therapies for PCNSL; however, the overall impact of this modality in brain lymphoma awaits further evaluation in ongoing studies The application of proteomic as well as gene expression technologies is yielding insights into PCNSL pathogenesis, in particular specific oncogenic pathways, which may be exploited to develop new therapies.

Original languageEnglish
Pages (from-to)43-51
Number of pages9
JournalLeukemia and Lymphoma
Volume49
Issue numberSUPPL. 1
DOIs
Publication statusPublished - 2008

Fingerprint

Lymphoma
Epidemiology
Central Nervous System
Pathology
Therapeutics
Radiation Effects
Highly Active Antiretroviral Therapy
Methotrexate
Brain Neoplasms
Proteomics
Anti-Idiotypic Antibodies
Acquired Immunodeficiency Syndrome
Steroids
Technology
Gene Expression
Incidence
Brain

Keywords

  • Biomarkers
  • Epidemiology
  • PCNSL
  • Primary CNS lymphoma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Primary lymphoma of the central nervous system : Epidemiology, pathology and current approaches to diagnosis, prognosis and treatment. / Rubenstein, James; Ferreri, Andres J M; Pittaluga, Stefania.

In: Leukemia and Lymphoma, Vol. 49, No. SUPPL. 1, 2008, p. 43-51.

Research output: Contribution to journalArticle

@article{a5911204504140cd890c96dde7abdb1c,
title = "Primary lymphoma of the central nervous system: Epidemiology, pathology and current approaches to diagnosis, prognosis and treatment",
abstract = "An overview of the current approaches to the management of patients with primary central nervous system lymphoma (PCNSL) is provided. Although accumulating evidence demonstrates that PCNSL is a curable type of brain tumor, in many cases establishing the diagnosis and overcoming chemotherapeutic resistance remain significant obstacles. The issue of treatment-related neurotoxicity is also a central consideration in treatment planning. The introduction of highly active antiretroviral therapy has had a major impact on this disease in that the incidence of AIDS-related central nervous system lymphoma, once highly prevalent in the 1980s and 1990s, has now virtually disappeared. However, the problem of diagnostic delays secondary to steroid effects, radiation-induced neurotoxicity and methotrexate resistance represent unique and important problems in this disease. The use of anti-CD20 antibody in this disease represents the first application of biologically based targeted therapies for PCNSL; however, the overall impact of this modality in brain lymphoma awaits further evaluation in ongoing studies The application of proteomic as well as gene expression technologies is yielding insights into PCNSL pathogenesis, in particular specific oncogenic pathways, which may be exploited to develop new therapies.",
keywords = "Biomarkers, Epidemiology, PCNSL, Primary CNS lymphoma",
author = "James Rubenstein and Ferreri, {Andres J M} and Stefania Pittaluga",
year = "2008",
doi = "10.1080/10428190802311441",
language = "English",
volume = "49",
pages = "43--51",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor and Francis Ltd.",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Primary lymphoma of the central nervous system

T2 - Epidemiology, pathology and current approaches to diagnosis, prognosis and treatment

AU - Rubenstein, James

AU - Ferreri, Andres J M

AU - Pittaluga, Stefania

PY - 2008

Y1 - 2008

N2 - An overview of the current approaches to the management of patients with primary central nervous system lymphoma (PCNSL) is provided. Although accumulating evidence demonstrates that PCNSL is a curable type of brain tumor, in many cases establishing the diagnosis and overcoming chemotherapeutic resistance remain significant obstacles. The issue of treatment-related neurotoxicity is also a central consideration in treatment planning. The introduction of highly active antiretroviral therapy has had a major impact on this disease in that the incidence of AIDS-related central nervous system lymphoma, once highly prevalent in the 1980s and 1990s, has now virtually disappeared. However, the problem of diagnostic delays secondary to steroid effects, radiation-induced neurotoxicity and methotrexate resistance represent unique and important problems in this disease. The use of anti-CD20 antibody in this disease represents the first application of biologically based targeted therapies for PCNSL; however, the overall impact of this modality in brain lymphoma awaits further evaluation in ongoing studies The application of proteomic as well as gene expression technologies is yielding insights into PCNSL pathogenesis, in particular specific oncogenic pathways, which may be exploited to develop new therapies.

AB - An overview of the current approaches to the management of patients with primary central nervous system lymphoma (PCNSL) is provided. Although accumulating evidence demonstrates that PCNSL is a curable type of brain tumor, in many cases establishing the diagnosis and overcoming chemotherapeutic resistance remain significant obstacles. The issue of treatment-related neurotoxicity is also a central consideration in treatment planning. The introduction of highly active antiretroviral therapy has had a major impact on this disease in that the incidence of AIDS-related central nervous system lymphoma, once highly prevalent in the 1980s and 1990s, has now virtually disappeared. However, the problem of diagnostic delays secondary to steroid effects, radiation-induced neurotoxicity and methotrexate resistance represent unique and important problems in this disease. The use of anti-CD20 antibody in this disease represents the first application of biologically based targeted therapies for PCNSL; however, the overall impact of this modality in brain lymphoma awaits further evaluation in ongoing studies The application of proteomic as well as gene expression technologies is yielding insights into PCNSL pathogenesis, in particular specific oncogenic pathways, which may be exploited to develop new therapies.

KW - Biomarkers

KW - Epidemiology

KW - PCNSL

KW - Primary CNS lymphoma

UR - http://www.scopus.com/inward/record.url?scp=53249095570&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53249095570&partnerID=8YFLogxK

U2 - 10.1080/10428190802311441

DO - 10.1080/10428190802311441

M3 - Article

C2 - 18821432

AN - SCOPUS:53249095570

VL - 49

SP - 43

EP - 51

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - SUPPL. 1

ER -